A European Trial to Assess the Efficacy of an Implantable Wireless Neuromodulation Device at the Tibial Nerve to Treat Urinary Urgency Incontinence
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- Uro Medical Corporation
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Reduction in Urge Incontinence Episodes
Study Overview
Brief Summary
30 patient Study. All patients implanted with StimGuard Protect System. Patient followed out to 90 days.
Detailed Description
The proposed therapy is called chronic tibial nerve stimulation (CTNS), which is a low-risk, minimally invasive chronic implant for the treatment of urgency urinary incontinence. CTNS works by the same mechanism as percutaneous tibial nerve stimulation (PTNS), but is provided for chronic use with an implantable device. CTNS treatment involves the placement of a minimally invasive stimulator with an embedded receiver at the tibial nerve. The Protect CTNS System has an external transmitter that activates the implanted stimulator and sends mild electrical pulses to the tibial nerve. These impulses travel to the sacral nerve plexus, the group of nerves at the base of the spine responsible for bladder function. Since stimulation with the Protect CTNS System is chronic it is expected that bladder activity can be changed more quickly and without the frequency of treatments related to PTNS.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of overactive bladder with urgency urinary incontinence
Exclusion Criteria
- •Primary complaint of stress urinary incontinence
Arms & Interventions
Chronic Tibial Implant Arm
StimGuard Protect System (Chronic Tibial Nerve Stimulation) Implant Procedure. Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
Intervention: Device: StimGuard Protect System (Device)
Outcomes
Primary Outcomes
Reduction in Urge Incontinence Episodes
Time Frame: 90 days
Secondary Outcomes
No secondary outcomes reported
